

BRUSSELS NOTICE NO. BRU12-13

Issue Date:

29 November 2012

Effective Date:

30 November 2012

INTRODUCTION OF OPTIONS ON THROMBOGENICS

Executive Summary

Trading in options on ThromboGenics (THR) on the Euronext Brussels derivatives markets will start on 30 November 2012 at 9:01 a.m. (CET).

1. NYSE Liffe hereby announces that trading in options on ThromboGenics (THR) on the Euronext Brussels derivatives market will start on 30 November 2012 at 9:01 a.m. (CET).
2. The following Members have been selected as Primary Market Maker:
 - All Options International B.V.
3. The following Member have been selected as Competitive Market Maker:
 - B&Bt NV
4. The above mentioned Liquidity Providers on the derivatives market should comply with the maximum spreads and minimum size obligations as mentioned in the Appendix (page 7). These conditions will be applicable up to and including 31 October 2013.
5. With reference to [Brussels Notice BRU12-12 Introduction of ThromboGenics stock options](#), NYSE Liffe furthermore announces that category 3 price limits will apply to THR. In this category, price limits are applied on each side of the reference price ("base level") as shown in the table below:

Expiration months ≤12 months				
Individual Equity Options Category 3				
Series having a premium	Series having a premium	Series having a premium	Series having a premium	Series having a premium
≤ 0.50	>0.50 ≤ 1.50	>1.50 ≤ 5.00	>5.00 ≤ 15.00	> 15.00
base level	base level	base level	base level	base level
+/- € 0.30	+/- € 0.40	+/- € 0.60	+/- € 0.80	+/- € 1.00

See: <https://globalderivatives.nyx.com/documentation/price-limits>

6. As from Friday 30 November 2012 after close of business THR option series will be published on our website via:
<https://globalderivatives.nyx.com/nyse-liffe/product-news>

For further information in relation to this Notice, Members should contact:

EMS Liquidity Provision

+31 (0)20 550 5110

ELPS@nyx.com

The **Euronext Derivatives Markets** comprise the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets. Euronext is part of the NYSE Euronext group.

Euronext N.V., PO Box 19163, 1000 GD Amsterdam, The Netherlands

globalderivatives.nyx.com

BRUSSELS MEDEDELING NO. BRU12-13

Uitgiftedatum:

29 november 2012

Datum inwerkingtreding:

30 november 2012

INTRODUCTIE VAN OPTIES OP THROMBOGENICS

Samenvatting

De handel in opties met als onderliggende waarde het aandeel ThromboGenics (THR) via de Euronext Brussels derivatenmarkt zal aanvangen op 30 november 2012 om 9:01 (CET).

1. NYSE Liffe deelt u mede dat de handel in opties met als onderliggende waarde het aandeel ThromboGenics (THR) op de derivatenmarkt van Euronext Brussel zal aanvangen op 30 november 2012 om 9:01 CET).
2. De volgende Leden zijn geselecteerd als Primary Market Maker:
 - All Options International B.V.
3. De volgende Leden zijn geselecteerd als Competitive Market Maker:
 - B&Bt NV
4. Bovenstaande Liquidity Providers dienen zich te houden aan de maximum spreads en de minimum size verplichtingen zoals vermeld in de bijlage van deze notice (Appendix, pagina 7). Deze voorwaarden gelden tot en met 31 oktober 2013.
5. Onder verwijzing naar [Brussels Mededeling BRU12-12 Introductie aandelenopties op ThromboGenics](#), deelt NYSE Liffe tevens mede dat de prijslimieten zullen vallen in categorie 3. In deze categorie worden de prijslimieten aan weerszijden van de referentieprij ("base level") als volgt vastgesteld:

Expiration months ≤12 months				
Individual Equity Options Category 3				
Series having a premium	Series having a premium	Series having a premium	Series having a premium	Series having a premium
≤ 0.50	>0.50 ≤ 1.50	>1.50 ≤ 5.00	>5.00 ≤ 15.00	> 15.00
base level	base level	base level	base level	base level
+/- € 0.30	+/- € 0.40	+/- € 0.60	+/- € 0.80	+/- € 1.00

Zie: <https://globalderivatives.nyx.com/documentation/price-limits>

The **Euronext Derivatives Markets** comprise the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets. Euronext is part of the NYSE Euronext group.

Euronext N.V., PO Box 19163, 1000 GD Amsterdam, The Netherlands

globalderivatives.nyx.com

6. Vanaf vrijdag 30 november 2012 na het sluiten van de handel worden de series van THR gepubliceerd op onze website via volgende link:
<https://globalderivatives.nyx.com/nl/nyse-liffe/product-news>

Voor aanvullende informatie met betrekking tot deze Notice, verzoeken wij Members contact op te nemen met:

EMS Liquidity Provision +31 (0)20 550 5110 ELPS@nyx.com

The **Euronext Derivatives Markets** comprise the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets. Euronext is part of the NYSE Euronext group.

Euronext N.V., PO Box 19163, 1000 GD Amsterdam, The Netherlands

globalderivatives.nyx.com

BULLETIN BRUXELLES NO. BRU12-13

Date de publication:

29 novembre 2012

Date effective:

30 novembre 2012

INTRODUCTION DES OPTIONS SUR L'ACTION THROMBOGENICS

Sommaire

Les options sur l'action ThromboGenics (THR) sur le marché des dérivés d'Euronext Brussels seront ouvertes à la négociation à partir du 30 novembre 2012 à 9h01 (CET).

1. NYSE Liffe annonce que les options sur actions ThromboGenics (THR) sur le marché des dérivés d'Euronext Brussels seront ouvertes à la négociation à partir du 30 novembre 2012 à 9h01 (CET).
2. Les Membres suivants ont été sélectionnés comme Primary Market Maker:
 - All Options International B.V.
3. Les Membres suivants ont été sélectionnés comme Competitive Market Maker:
 - B&Bt NV
4. Les Apporteurs de Liquidité (« Liquidity Providers ») mentionnés ci-dessus doivent se conformer aux obligations des écarts maximaux et des tailles minimales décrites dans l'annexe du présent Bulletin (Appendix, page 7). Ces conditions seront effectives jusqu'au 31 octobre 2013 inclus.
5. Faisant référence au [Bulletin Bruxelles BRU12-12 Introduction d'options sur l'action ThromboGenics](#), NYSE Liffe annonce que les options THR tombent dans les limites de prix de la catégorie 3. Dans cette catégorie, les limites de prix s'appliquent aux deux versants du prix de référence ("base level"), comme indiqué dans le tableau ci-dessous:

Expiration months ≤12 months				
Individual Equity Options Category 3				
Series having a premium	Series having a premium	Series having a premium	Series having a premium	Series having a premium
≤ 0.50	>0.50 ≤ 1.50	>1.50 ≤ 5.00	>5.00 ≤ 15.00	> 15.00
base level	base level	base level	base level	base level
+/- € 0.30	+/- € 0.40	+/- € 0.60	+/- € 0.80	+/- € 1.00

Voir: <https://globalderivatives.nyx.com/documentation/price-limits>

The Euronext Derivatives Markets comprise the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets. Euronext is part of the NYSE Euronext group.

Euronext N.V., PO Box 19163, 1000 GD Amsterdam, The Netherlands

globalderivatives.nyx.com

6. A la date du vendredi 30 novembre 2012, après la clôture des marchés, les séries d'options THR seront publiées sur notre site via:

<https://globalderivatives.nyx.com/fr/nyse-liffe/product-news>

Pour des informations complémentaires, nous vous prions de contacter:

EMS Liquidity Provision

+31 (0)20 550 5110

ELPS@nyx.com

The **Euronext Derivatives Markets** comprise the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets. Euronext is part of the NYSE Euronext group.

Euronext N.V., PO Box 19163, 1000 GD Amsterdam, The Netherlands

globalderivatives.nyx.com

Appendix to Brussels Notice BRU12-13

Minimum size and maximum spread obligations of ThromboGenics:

		THR
Term:	Bid price:	Maximum spreads
=<12 months	0.00 - 0.50	0.25
	0.51 - 2.50	0,40
	2.51 - 5.00	0.50
	5.01 - 10.00	0.90
	10.01 - 20.00	1.25
	20.01 - 30.00	1.75
	30.01 - 40.00	3.50
	> 40.00	4.50
minimum size		2
guaranteed % of turnover (PMM)		10%

The **Euronext Derivatives Markets** comprise the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets. Euronext is part of the NYSE Euronext group.

Euronext N.V., PO Box 19163, 1000 GD Amsterdam, The Netherlands

globalderivatives.nyx.com